Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.
about
Real-world data in the molecular era-finding the reality in the real world.10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation studyInitial computed tomography imaging details during first-line systemic therapy is of significant prognostic value in patients with naïve, unresectable metastatic renal cell carcinoma.Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome.RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities.Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies.Sonographically Identified Echogenic Renal Masses Up to 1 cm in Size Are So Rarely Malignant They Can Be Safely Ignored.Diffusion-weighted quantitative MRI of pleural abnormalities: Intra- and interobserver variability in the apparent diffusion coefficient measurements.Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.Inter- and intra-rater reliability of calliper-based lymph node measurement in dogs with peripheral nodal lymphomasOptimal Phase of Dynamic Computed Tomography for Reliable Size Measurement of Metastatic Neuroendocrine Tumors of the Liver: Comparison between Pre- and Post-Contrast PhasesImaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges
P2860
Q31023009-8F81E440-10A9-4EB1-A820-D0B7366CC0D1Q33577856-915BDD33-DAC5-41EA-8601-0BEA31FD9FE1Q33745827-F1DFE5EC-E506-4A5B-814D-36102077B483Q34537285-08E5D306-9815-4FDC-8035-34C1CE9D595AQ35156636-3CCFB2A9-5C38-4636-A269-EE314CC806F9Q37589551-FD7F054C-18D2-447F-94F1-32179874E3EEQ38837758-FB7E0CC5-456B-4AF6-B408-53B294C2D1ADQ47334721-7CDBB7AC-42C4-4CE9-BAA9-8BC33C544FA8Q47997434-933D63B3-8F4D-449B-B228-3BD5D39D7316Q48771882-858A41CA-4F03-47F3-A64B-F1FCF07C9C53Q57541210-72B0F531-5EC1-4A00-8C08-7A88CAE1737FQ58565402-090236EA-A30C-4656-A798-D843C14742A3Q58585071-F6B99F34-0EC2-4635-BED8-029BE6017164
P2860
Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Intraobserver and interobserve ...... alternative response criteria.
@ast
Intraobserver and interobserve ...... alternative response criteria.
@en
type
label
Intraobserver and interobserve ...... alternative response criteria.
@ast
Intraobserver and interobserve ...... alternative response criteria.
@en
prefLabel
Intraobserver and interobserve ...... alternative response criteria.
@ast
Intraobserver and interobserve ...... alternative response criteria.
@en
P2093
P2860
P356
P1433
P1476
Intraobserver and interobserve ...... alternative response criteria.
@en
P2093
Annick D Van den Abbeele
Katherine M Krajewski
Mizuki Nishino
Nikhil H Ramaiya
Toni K Choueiri
Yoko Franchetti
P2860
P304
P356
10.1002/CNCR.28493
P407
P577
2013-11-21T00:00:00Z